QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

LEGN

QT72Legend Biotech Corporation
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
27.93
-5.59-16.68%
OverviewShort InterestFilings
LEGNQT72Legend Biotech Corporation·NASDAQ
OverviewShort InterestFilings
27.93-16.68%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.37
Insider Own0.07%
Shs Outstand371.48M
Perf Week-23.02%
Market Cap6.20BForward P/E30.34EPS next Y0.92Insider Trans-0.00%Shs Float-Perf Month3.67%
Enterprise Value5.94BPEG0.57EPS next Q0.12Inst Own-Short Float-Perf Quarter56.30%
Income-250451539.00P/S5.44EPS this Y106.66%Inst Trans-Short Ratio-Perf Half Y29.01%
Sales1.14BP/B6.40EPS next Y909.25%ROA-15.67%Short Interest-Perf YTD28.47%
Book/sh2.61P/C-EPS next 5Y119.70%ROE-24.91%52W High45.30 -38.34%Perf Year-19.51%
Cash/sh2.25P/FCF-EPS past 3/5Y-ROIC-9.95%52W Low16.24 71.98%Perf 3Y-
Dividend Est.-EV/EBITDA-32.82Sales past 3/5Y106.42% 68.84%Gross Margin54.99%Volatility6.43% 5.99%Perf 5Y-
Dividend TTM-EV/Sales5.22EPS Y/Y TTM29.90%Oper. Margin-11.92%ATR (14)2.59Perf 10Y-
Dividend Ex-Date-Quick Ratio2.05Sales Y/Y TTM81.50%Profit Margin-21.97%RSI (14)42.95Recom2.14
Dividend Gr. 3/5Y-Current Ratio2.13EPS Q/Q-114.29%SMA20-12.41%Beta0.57Target Price58.00
Payout0.00%Debt/Eq0.40Sales Q/Q56.41%SMA501.50%Rel Volume4.60Prev Close33.52
Employees2,600LT Debt/Eq0.09EarningsAug 10SMA2008.58%Avg Volume2.95MPrice27.93
IPO DateJun 05, 2020Option/ShortYes / YesEPS/Sales Surpr.-650.00% -0.65%Net Debt/EBITDA1.42Volume13,592,567Change-16.68%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-03-26ReiteratedH.C. Wainwright$50 → $65
Jun-03-26ReiteratedUBSBuy$50 → $49
Jun-01-26ReiteratedUBSBuy$48 → $50
May-13-26ReiteratedMorgan StanleyOverweight$49 → $48
May-13-26ReiteratedRBC CapitalOutperform$62 → $64
Mar-11-26ReiteratedMorgan StanleyOverweight$50 → $49
Mar-11-26ReiteratedRBC CapitalOutperform$66 → $62
Mar-10-26ReiteratedTruist Financial$88 → $70
Mar-10-26ReiteratedJefferiesBuy$21 → $69
Feb-12-26ReiteratedRedburn Partners$86 → $24
Latest News
Jun-18-26
Jun-18-2608:27AM
Why Is Legend Biotech Stock Falling Thursday?Benzinga
08:02AM
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga
06:10AM
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving PremarketBenzinga
Jun-17-26
Jun-17-2604:30PM
Legend Biotech Commences $225M Offering Of Its American Depositary SharesBenzinga
Jun-15-26
Jun-15-2603:04AM
Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,1381,029627
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A512408235
Gross Profit626621393
Selling, General and Administrative Excl. Other359342284
Research and Development398415414
Other Operating Expense50-2
Operating Income-136-136-303
Interest Expense222122
Unusual Expense
———
Non-Operating Income (Expense)86125-167
Net Income Before Taxes-237-283-158
Income Taxes141419
Consolidated Net Income-250-297-177
Net Income From Continuing Operations-250-297-177
Net Income-250-297-177
EPS (Recurring)-1.36-1.60-0.97
EPS (Basic, Before Extraordinaries)-1.36-1.60-0.97
EPS (Diluted)-1.37-1.60-0.97
EBITDA-181-232-113
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio4.543.89—
Gross Margin55.0160.3562.68
Operating Margin-11.95-13.22-48.33
Net Margin-21.97-28.86-28.23
Shares Outstanding185184183
Market Capitalization5,1674,000—
Operating Lease Expense
———
Insider Trading Volume
$30.11$28.04$25.96$23.89$21.82● Close Price0.00K21.78K43.57K65.35K87.14KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Huang YingChief Executive OfficerMar 25 '26Sale8.779,93687,139247,438Mar 27 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR